Literature DB >> 28039670

Hepatic Encephalopathy Is Associated with Persistent Learning Impairments Despite Adequate Medical Treatment: A Multicenter, International Study.

Silvia Nardelli1, Sanath Allampati2, Oliviero Riggio1, Kevin D Mullen2, Ravi Prakash2, Stefania Gioia1, Ariel Unser3, Melanie B White3, Andrew C Fagan3, James B Wade4, Alessio Farcomeni5, Edith A Gavis3, Jasmohan S Bajaj6.   

Abstract

BACKGROUND: Hepatic encephalopathy (HE) is considered reversible regarding mental status but may not be cognitively in single-center studies. AIM: To evaluate persistence of learning impairment in prior HE compared to those who never experienced HE (no-HE) in a multicenter study.
METHODS: A total of 174 outpatient cirrhotics from three centers (94 Virginia, 30 Ohio, and 50 Rome; 36 prior HE) underwent psychometric hepatic encephalopathy score (PHES) and inhibitory control (ICT) testing at baseline and then at least 7 days apart. ICT learning (change in 2nd half lures compared to 1st half) was compared between patient groups at both visits. Change in the PHES individual sub-tests and total score between visits was compared in both groups. US versus Italian trends were also analyzed.
RESULTS: HE patients had worse PHES and ICT results compared to no-HE patients at baseline. Significant improvement (1st half 7.1 vs. 2nd half 6.2, p < 0.0001) was observed in no-HE, but not in HE (1st half 7.9 vs. 2nd half 7.8, p = 0.1) at baseline. At retesting (median 20 days later), no-HE patients continued with significant learning (1st half 6.0 vs. 2nd half 5.4, p < 0.0001), while HE patients again did not improve (1st half 7.8 vs. 2nd half 6.9, p = 0.37). Between visits, no-HE patients improved significantly on four PHES sub-tests and overall score, while HE patients only improved on two sub-tests with similar overall PHES score. Trends were similar between US and Italian subjects.
CONCLUSION: In this multicenter study, prior HE patients showed persistent significant learning impairment compared to those without prior HE, despite adequate medical therapy. This persistent change should increase efforts to reduce the first HE episode.

Entities:  

Keywords:  Cirrhosis; Inhibitory control test; Lactulose; Psychometric hepatic encephalopathy score; Rifaximin

Mesh:

Substances:

Year:  2016        PMID: 28039670     DOI: 10.1007/s10620-016-4425-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  35 in total

1.  Cognitive correlates of job tenure among patients with severe mental illness.

Authors:  James M Gold; Richard W Goldberg; Scot W McNary; Lisa B Dixon; Anthony F Lehman
Journal:  Am J Psychiatry       Date:  2002-08       Impact factor: 18.112

2.  Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment.

Authors:  Matthew Calamia; Kristian Markon; Daniel Tranel
Journal:  Clin Neuropsychol       Date:  2012-04-30       Impact factor: 3.535

3.  Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts.

Authors:  Cristina Lucidi; Stefano Ginanni Corradini; Juan G Abraldes; Manuela Merli; Puneeta Tandon; Flaminia Ferri; Lucia Parlati; Barbara Lattanzi; Edoardo Poli; Vincenza Di Gregorio; Alessio Farcomeni; Oliviero Riggio
Journal:  Liver Transpl       Date:  2016-10       Impact factor: 5.799

Review 4.  MR imaging findings in hepatic encephalopathy.

Authors:  A Rovira; J Alonso; J Córdoba
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-26       Impact factor: 3.825

5.  Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma.

Authors:  L Zieve; W M Doizaki; J Zieve
Journal:  J Lab Clin Med       Date:  1974-01

6.  Increased manganese concentrations in pallidum of cirrhotic patients.

Authors:  G Pomier-Layrargues; L Spahr; R F Butterworth
Journal:  Lancet       Date:  1995-03-18       Impact factor: 79.321

7.  Cerebral cortical and white matter lesions in chronic hepatic encephalopathy: MR-pathologic correlations.

Authors:  Eiji Matsusue; Toshibumi Kinoshita; Eisaku Ohama; Toshihide Ogawa
Journal:  AJNR Am J Neuroradiol       Date:  2005-02       Impact factor: 3.825

8.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

9.  Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients.

Authors:  Federica Moscucci; Silvia Nardelli; Ilaria Pentassuglio; Chiara Pasquale; Lorenzo Ridola; Manuela Merli; Oliviero Riggio
Journal:  Liver Int       Date:  2011-08-15       Impact factor: 5.828

10.  Diagnosis of covert hepatic encephalopathy without specialized tests.

Authors:  Eiman Nabi; Leroy R Thacker; James B Wade; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Douglas M Heuman; Iliana Bouneva; Arun J Sanyal; Mohammad S Siddiqui; Velimir Luketic; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel Unser; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-19       Impact factor: 11.382

View more
  7 in total

1.  Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.

Authors:  Jasmohan S Bajaj; Nita H Salzman; Chathur Acharya; Richard K Sterling; Melanie B White; Edith A Gavis; Andrew Fagan; Michael Hayward; Mary L Holtz; Scott Matherly; Hannah Lee; Majdi Osman; Mohammad S Siddiqui; Michael Fuchs; Puneet Puri; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Hepatology       Date:  2019-06-18       Impact factor: 17.425

2.  Overt hepatic encephalopathy impairs learning on the EncephalApp stroop which is reversible after liver transplantation.

Authors:  Chathur Acharya; James B Wade; Andrew Fagan; Melanie White; Edith Gavis; Dinesh Ganapathy; HoChong Gilles; Douglas M Heuman; Jasmohan S Bajaj
Journal:  Liver Transpl       Date:  2017-11       Impact factor: 5.799

3.  Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.

Authors:  Guy Neff; Woodie Zachry
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

Review 4.  The Direct Contribution of Astrocytes and Microglia to the Pathogenesis of Hepatic Encephalopathy.

Authors:  Victoria Jaeger; Sharon DeMorrow; Matthew McMillin
Journal:  J Clin Transl Hepatol       Date:  2019-11-13

5.  Cognitive Impairment After Resolution of Hepatic Encephalopathy: A Systematic Review and Meta-Analysis.

Authors:  Óscar López-Franco; Jean-Pascal Morin; Albertina Cortés-Sol; Tania Molina-Jiménez; Diana I Del Moral; Mónica Flores-Muñoz; Gabriel Roldán-Roldán; Claudia Juárez-Portilla; Rossana C Zepeda
Journal:  Front Neurosci       Date:  2021-03-10       Impact factor: 4.677

Review 6.  The Association between Hepatic Encephalopathy and Diabetic Encephalopathy: The Brain-Liver Axis.

Authors:  So Yeong Cheon; Juhyun Song
Journal:  Int J Mol Sci       Date:  2021-01-05       Impact factor: 5.923

Review 7.  Hepatic Encephalopathy: From Metabolic to Neurodegenerative.

Authors:  Rafael Ochoa-Sanchez; Farzaneh Tamnanloo; Christopher F Rose
Journal:  Neurochem Res       Date:  2021-06-15       Impact factor: 3.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.